68906-27-4

Usage

Uses

Used in Pharmaceutical Research and Organic Synthesis:
(S)-2-Methyl-1-phenylpropan-1-aMine hydrochloride is used as a reagent for its role in the synthesis of various pharmaceuticals and organic compounds. Its chiral nature is crucial for the production of enantiomerically pure drugs, ensuring the desired biological activity and minimizing potential side effects.
Used in the Production of Chiral Drugs:
In the pharmaceutical industry, (S)-2-Methyl-1-phenylpropan-1-aMine hydrochloride is utilized as a key intermediate in the synthesis of chiral drugs. (S)-2-Methyl-1-phenylpropan-1-aMine hydrochloride's ability to create non-superimposable mirror images allows for the development of drugs that are more effective and have fewer side effects due to their specific interactions with biological targets.
Used in Neurotransmitter Research:
(S)-2-Methyl-1-phenylpropan-1-aMine hydrochloride is used as a subject of study in neurotransmitter research. Its potential as a neurotransmitter highlights its importance in understanding and potentially influencing central nervous system functions.
Used in the Treatment of Central Nervous System Disorders:
In the medical field, especially in neurology and psychiatry, (S)-2-Methyl-1-phenylpropan-1-aMine hydrochloride is being investigated for its potential use in treating conditions such as depression and anxiety. Its pharmacological effects on the central nervous system make it a promising candidate for developing new therapeutic agents.
Each application underscores the versatility and importance of (S)-2-Methyl-1-phenylpropan-1-aMine hydrochloride in advancing chemical, pharmaceutical, and medical research and development.

Upstream product

• 7699-79-8 benzhydrylidene-benzyl-amine 
• 75-26-3 isopropyl bromide 
• 220315-19-5 (R,E)-2-methyl-N-(2-methylpropylidene)propane-2-sulfinamide 
• 108-86-1 bromobenzene 
• 1175603-96-9 S_s-2-methyl-propane-2-sulfinic acid [2-methylpropylidene]amide 
• 1315318-10-5 (S)-2,4,6-trimethyl-N-((S)-2-methyl-1-phenylpropyl)-benzenesulfinamide 
• 186249-76-3 (R,E)-2-methyl-N-(phenylmethylene)-2-propanesulfinamide 
• 100-52-7 benzaldehyde 
• 196929-98-3 (R_S,S)-N-(2-methyl-1-phenylpropyl)-2-methylpropylsulfinamide 
• 196929-93-8 (R_S,R)-N-(2-methyl-1-phenylpropyl)-2-methylpropane-2-sulfinamide 
• 72846-70-9 isopropyl phenyl ketoxime 

Downstream Products

• 56010-63-0 2,2-dimethyl-3-hydroxy-1-phenylpropan-1-one 
• 6668-27-5 (S)-2-methyl-1-phenylpropane-1-amine 

Relevant academic research and scientific papers

Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H2R and D3R

Even today, the role of the histamine H2 receptor (H2R) in the central nervous system (CNS) is widely unknown. In previous research, many dimeric, high-affinity and subtype-selective carbamoylguanidine-type ligands such as UR-NK22 (5, pKi = 8.07) were reported as H2R agonists. However, their applicability to the study of the H2R in the CNS is compromised by their molecular and pharmacokinetic properties, such as high molecular weight and, consequently, a limited bioavailability. To address the need for more drug-like H2R agonists with high affinity, we synthesized a series of monomeric (thio)carbamoylguanidine-type ligands containing various spacers and side-chain moieties. This structural simplification resulted in potent (partial) agonists (guinea pig right atrium, [35S]GTPγS and β-arrestin2 recruitment assays) with human (h) H2R affinities in the one-digit nanomolar range (pKi (139, UR-KAT523): 8.35; pKi (157, UR-MB-69): 8.69). Most of the compounds presented here exhibited an excellent selectivity profile towards the hH2R, e.g. 157 being at least 3800-fold selective within the histamine receptor family. The structural similarities of our monomeric ligands to pramipexole (6), a dopamine receptor agonist, suggested an investigation of the binding behavior at those receptors. The target compounds were (partial) agonists with moderate affinity at the hD2longR and agonists with high affinity at the hD3R (e.g. pKi (139, UR-KAT523): 7.80; pKi (157, UR-MB-69): 8.06). In summary, we developed a series of novel, more drug-like H2R and D3R agonists for the application in recombinant systems in which either the H2R or the D3R is solely expressed. Furthermore, our ligands are promising lead compounds in the development of selective H2R agonists for future in vivo studies or experiments utilizing primary tissue to unravel the role and function of the H2R in the CNS.

APPLICATIONS OF N6-SUBSTITUTED ADENOSINE DERIVATIVE AND N6-SUBSTITUTED ADENINE DERIVATIVE TO CALMING, HYPNOSES, CONVULSION RESISTANCE, EPILEPTIC RESISTANCE, PARKINSON DISEASE RESISTANCE, AND DEMENTIA PREVENTION AND TREATMENT

PROBLEM TO BE SOLVED: To prepare analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. SOLUTION: The present invention relates to an N6-substituted adenosine derivative and an N6-substituted adenine derivative selected from the group consisting of specific compounds. The present invention also relates to a pharmaceutical composition at least comprising a therapeutically effective amount of the compounds and a pharmaceutically acceptable carrier. The invention further relates to the compounds used in preparation of analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. COPYRIGHT: (C)2016,JPO&INPIT

Reversal diastereoselectivity between the organomagnesium and organolithium reagents on Chiral N-tert-butylsulfinylaldimines for the preparation of chiral amines

The asymmetric synthesis of both the enantiomer of chiral amines from the single chiral source of N-tert-butylsulfinylaldimines (3) by simply changing the organometallic reagents through diastereoselective addition. An efficient enantioselective synthesis of chiral amines including (S)-3-methyl-1-(2- piperidin-1-yl-phenyl)butyl amine (6a), a key intermediate to prepare antidiabetic drug repaglinide (1), is reported.

Intermolecular alkyl radical additions to enantiopure N-tert-butanesulfinyl aldimines

The sulfinyl group in (R)-N-tert-butanesulfinyl aldimines provides efficient control of the stereoselectivity in the intermolecular reactions with alkyl radicals. The methodology is applicable to aryl, heteroaryl, benzyl, and alkynyl imines, even those containing CN, CO2Me, COR, and OH groups. The best results are attained with hindered radicals (tertiary and secondary ones) without C=N bond reduction. This reaction complements the well-established organometallic additions to N-sulfinyl aldimines to obtain enantiomerically pure functionalized α-branched primary amines.

N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

One-pot synthesis of chiral nonracemic amines

One-pot five-component reactions of oxathiazolidine-S-oxides with mesitylmagnesium bromide, lithium bis(trimethylsilyl)amide, aldehydes and Grignard reagents afford chiral nonracemic amines or sulfinamides in good yields and high stereoselectivities.

PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS

The present invention relates to compound of formula (I) useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.

ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS

Isoquinolone derivatives of the general formula are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.

Asymmetric synthesis of chiral amines by highly diastereoselective 1,2- additions of organometallic reagents to N-tert-butanesulfinyl imines

High yielding and highly diastereoselective methods for 1,2-additions of organometallic reagents to N-tert-butanesulfinyl aldimines (2) and N-tert- butanesulfinyl kerimines (3) are described. The additions of alkyl, aryl, alkenyl, and allyl carbanions to a diverse set of imines with different steric and electronic properties are demonstrated. Acidic methanolysis of the sulfinamide products (4 and 6) delivers highly enantioenriched α-branched and α,α-dibranched amines. Since a broad range of sulfinyl imines are easily accessible from aldehydes and ketones, a wide variety of enantioentriched amines may be prepared.